- Home
- PRTA
as 05-16-2025 4:00pm EST
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
| Founded: | 2012 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 809.8M | IPO Year: | N/A |
| Target Price: | $51.71 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.00 - $25.42 | Next Earning Date: | 05-08-2025 |
| Revenue: | $137,935,000 | Revenue Growth: | 54.55% |
| Revenue Growth (this year): | -61.47% | Revenue Growth (next year): | 122.59% |
Stock Insider Trading Activity of Prothena Corporation plc (PRTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | PRTA | 10% Owner | May 2 '25 | Sell | $8.04 | 6,279,684 | $50,839,807.34 | 8,266,342 |
Latest Prothena Corporation plc News
PRTA Breaking Stock News: Dive into PRTA Ticker-Specific Updates for Smart Investing
Zacks
10 days ago
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
MT Newswires
10 days ago
RBC Trims Price Target on Prothena to $18 From $20, Keeps Sector Perform, Speculative Risk
Insider Monkey
11 days ago
Is Prothena Corporation plc (PRTA) the Low Risk High Reward Stock Set to Triple by 2030?
Zacks
11 days ago
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
Associated Press Finance
11 days ago
Prothena: Q1 Earnings Snapshot
Business Wire
11 days ago
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
Simply Wall St.
15 days ago
Insiders Re-Evaluate Their US$2.75m Stock Purchase As Prothena Falls To US$458m
MT Newswires
17 days ago
Prothena Corp Public Ltd Insider Bought Shares Worth $2,749,916, According to a Recent SEC Filing
Compare PRTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRTA Prothena Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.